Health care stocks were rising Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.6%.
The iShares Biotechnology ETF (IBB) added 1.1%.
In corporate news, Novo Nordisk (NVO) said it launched a direct-to-patient delivery option that offers patients all dose strengths of Wegovy at a reduced cost. Novo shares gained 3.4%.
Amgen (AMGN) has started two phase 3 trials for its obesity drug MariTide, the company's Head of Research and Development, Jay Bradner, said Wednesday at an investor conference. Amgen shares rose 1.4%.
Merck (MRK) is facing a patent dispute that threatens its plans to sell a new version of Keytruda, its top-selling cancer drug, the Wall Street Journal reported. Merck shares were fractionally higher.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。